Dr. Steidl and Scott teams have successfully won a large-scale applied research project grant worth $11.9 million funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to study the genome biology of relapsed lymphoid cancers. Our large-scale, pan-Canadian study was launched to discover novel, actionable markers of relapsed lymphoma from which clinically relevant assays can be developed. This study also aims to implement genomic-based clinical assays, which have been previously developed by our research team, in the publicly funded health care system across the country to enhance more patient -centric approaches and improve outcomes for lymphoma patients.

Back to top